MK5172 is primarily utilized in the pharmaceutical industry as a potent inhibitor of the hepatitis C virus (HCV) NS3/4A protease. It plays a crucial role in antiviral therapies, particularly in combination with other drugs to enhance efficacy and reduce viral resistance. Its application is significant in the development of treatments for chronic hepatitis C, helping to achieve sustained virologic response and improve patient outcomes. Additionally, MK5172 is studied for its potential in targeting other viral infections where protease inhibition is beneficial, contributing to broader antiviral research and drug development.